3-27-2017

Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population

George Kouris
University of Massachusetts Medical School

Tasmina Hydery
University of Massachusetts Medical School

Bonnie C. Greenwood
University of Massachusetts Medical School

See next page for additional authors

Follow this and additional works at: http://escholarship.umassmed.edu/commed_pubs

Part of the Health Services Administration Commons, Health Services Research Commons, Pharmacy and Pharmaceutical Sciences Commons, and the Virus Diseases Commons

Recommended Citation
Kouris, George; Hydery, Tasmina; Greenwood, Bonnie C.; Lavitas, Pavel; Alper, Caroline J.; Price, Mylissa K.; Clements, Karen M.; Lenz, Kimberly J.; and Jeffrey, Paul L., "Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population" (2017). Commonwealth Medicine Publications. 38.
http://escholarship.umassmed.edu/commed_pubs/38

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Commonwealth Medicine Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population

Authors

Keywords
Hepatitis C, Harvoni, ledipasvir, sofosbuvir, HCV genotype 1

Comments
Presented at the Academy of Managed Care and Specialty Pharmacy Annual Conference 2017.

Rights and Permissions
© 2017 University of Massachusetts Medical School
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population

INTRODUCTION

An estimated 2.7 to 3.9 million Americans suffer from chronic HCV infection. The primary goal of therapy in chronic HCV infection is eradication of HCV RNA, which is predicted by achievement of SVR12. Current treatment guidelines recommend treatment with antiviral medications for all patients with chronic HCV infection. HCV RNA levels as measured by PCR testing are used to determine therapy regimens.

METHODS

This retrospective cohort study utilized clinical and demographic data that is routinely compiled from PA requests for the comprehensive HCV medication management program of the MassHealth DRG program in an internal database, as well as pharmacy claims data from the MassHealth PFS.

OBJECTIVES

Primary Objective: To evaluate the effectiveness of HCV genotype 1 treatment with LDV/SOF, as measured by SVR12 in the MassHealth FFS and PCC plan population.

Secondary Objectives: To evaluate the effectiveness of HCV genotype 1 treatment with LDV/SOF within the subgroups of 8, 12, and 24-week regimens, and to identify predictors of treatment failure.

RESULTS

Table 1. Proportions of Members by Clinical and Demographic Variables, N (%) Table 2. Proportions of Members Who Achieved SVR12, N(%)

DISCUSSION

The proportion of members who achieved SVR12 overall is comparable to other real-world studies of LDV/SOF (Table 1). The proportion of members who achieved SVR12 in the MassHealth FFS and PCC plan population is comparable to other real-world studies of LDV/SOF (Table 2). The proportion of members achieving SVR12 is predicted by achievement of SVR12. Current treatment guidelines recommend treatment with antiviral medications for all patients with chronic HCV infection.

ABBREVIATIONS

DAA = direct-acting antiviral, DDI = drug-drug interaction, DUR = drug utilization review, FFS = fee-for-service, HCV = hepatitis C virus, HIV = human immunodeficiency virus, PA = prior authorization, PCC = Primary Care Clinician, PFS = Pharmacy and Outpatient System, SUD = substance use disorder, SVR12 = sustained virologic response 12 weeks, VA = Veterans Affairs

REFERENCES

LIMITATIONS

CONCLUSION

The proportion of members who achieved SVR12 overall is comparable to other real-world studies of LDV/SOF (Table 1). The proportion of members achieving SVR12 is predicted by achievement of SVR12. Current treatment guidelines recommend treatment with antiviral medications for all patients with chronic HCV infection.

The proportion of members who achieved SVR12 overall is comparable to other real-world studies of LDV/SOF (Table 2). The proportion of members achieving SVR12 is predicted by achievement of SVR12. Current treatment guidelines recommend treatment with antiviral medications for all patients with chronic HCV infection.